PMID: 19924668Nov 20, 2009Paper

In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones

European Journal of Ophthalmology
Bhavna ChawlaGita Satpathy

Abstract

To study the microbiological profile of bacterial keratitis in Northern India and to determine the antibiotic sensitivity pattern of bacterial keratitis isolates to fourth-generation fluoroquinolones. Laboratory records of all consecutive cases of clinically suspected bacterial corneal ulcers were retrospectively reviewed. Data noted included microorganism isolated and antibiotic culture sensitivity to cefazolin, tobramycin, gatifloxacin, and moxifloxacin. In vitro susceptibility toward individual antibiotics was determined and compared with the potential in vitro susceptibilities to cefazolin-tobramycin, cefazolin-gatifloxacin, and cefazolin-moxifloxacin combinations. A total of 292 bacterial isolates were identified. Of these, 255 (87.3%) were Gram-positive and 37 (12.7%) were Gram-negative. Staphylococcus epidermidis (n=227, 77.7%) was the most common organism. Overall susceptibility of isolates was 95.52% to gatifloxacin, 92.83% to moxifloxacin, 90.07% to tobramycin, and 83.56% to cefazolin (p<0.000). Organisms which showed resistance to fourth-generation fluoroquinolones included Staphylococcus epidermidis, Pseudomonas aeruginosa, viridans streptococci, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli....Continue Reading

References

Jul 15, 1991·American Journal of Ophthalmology·M J ShamiE Ai
Jul 15, 1991·American Journal of Ophthalmology·H H BrownR Y Foos
Jun 1, 1996·American Journal of Ophthalmology·K S BowerY J Gordon
Mar 20, 1998·The British Journal of Ophthalmology·M SrinivasanJ P Whitcher
Nov 30, 1999·American Journal of Ophthalmology·N A ChaudhryD Miller
Jun 26, 2001·The British Journal of Ophthalmology·F SchaeferY Guex-Crosier
Apr 5, 2002·American Journal of Ophthalmology·Rookaya MatherRegis P Kowalski
Feb 5, 2004·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Florentina LaspinaHerminia Miño de Kaspar
Feb 7, 2006·American Journal of Ophthalmology·Pragya ParmarChristdas Arul Nelson Jesudasan
Apr 25, 2006·Journal of Cataract and Refractive Surgery·Majid MoshirfarPaul C Kang
Sep 23, 2006·American Journal of Ophthalmology·Vincent A DeramoIra J Udell

❮ Previous
Next ❯

Citations

Sep 20, 2012·Journal of Ophthalmology·Raymond L M WongJimmy S M Lai
Feb 28, 2013·Expert Opinion on Pharmacotherapy·Darlene Miller
Nov 13, 2012·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Tushar AgarwalJeewan S Titiyal
Jun 25, 2015·Asia-Pacific Journal of Ophthalmology·Bibhudutta RautarayaSrikant K Sahu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.